Century Therapeutics, Inc. Operating Lease, Payments
Century Therapeutics, Inc. (IPSC) reported Operating Lease, Payments of $5.26 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2023-03-16
- Century Therapeutics, Inc. operating lease, payments for the quarter ending 2021-12-31 was -$135.00K, a 114.17% decline year-over-year.
- Century Therapeutics, Inc. operating lease, payments for the quarter ending 2021-09-30 was $44.00K, a 83.27% decline year-over-year.
- Century Therapeutics, Inc. operating lease, payments for the quarter ending 2021-06-30 was $5.00K.
- Century Therapeutics, Inc. operating lease, payments for the quarter ending 2021-03-31 was $127.00K.
- Century Therapeutics, Inc. operating lease, payments for fiscal 2022 was $5.26M, a 12724.39% increase from fiscal 2021.
- Century Therapeutics, Inc. operating lease, payments for fiscal 2021 was $41.00K, a 98.11% decline from fiscal 2020.
- Century Therapeutics, Inc. operating lease, payments for fiscal 2020 was $2.17M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2022-12-31 | $5.26M 10-K · filed 2023-03-16 | |||
| 2021-12-31 | -$135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$91.00K derived: sum of 2 quarters · filed 2022-11-10 | -$86.00K derived: sum of 3 quarters · filed 2022-11-10 | $41.00K 10-K · filed 2022-03-17 |
| 2021-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $49.00K derived: sum of 2 quarters · filed 2022-11-10 | $176.00K 10-Q · filed 2022-11-10 | $1.13M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $132.00K 10-Q · filed 2022-08-11 | $1.08M derived: sum of 3 quarters · filed 2022-08-11 | $1.35M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $127.00K 10-Q · filed 2022-05-16 | $1.08M derived: sum of 2 quarters · filed 2022-05-16 | $1.34M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $953.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.22M derived: sum of 2 quarters · filed 2022-03-17 | $2.17M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $263.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.22M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $959.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |